TABLE OF CONTENTS
1. EXECUTIVE SUMMARY
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3.Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2.Breakdown of Primary Respondents
3.5. Forecasting Model
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Value Chain Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis
6. GLOBAL ONCOLOGY BIOSIMILARS MARKET, BY DRUG
6.1. Overview
6.2. G-CSF
6.3. Monoclonal Antibody
6.4. Hematopoietic Agents
7. GLOBAL ONCOLOGY BIOSIMILARS MARKET, BY DISEASE INDICATION
7.1. Overview
7.2. Breast Cancer
7.3. Non-Small Cell Lung Cancer
7.4. Colorectal Cancer
7.5. Neutropenia
7.6. Blood Cancer
7.7. Leukemia
7.7.1. Myeloid Leukemia
7.7.2. Chronic Lymphocytic Leukemia
7.7.3. Non-Hodgkin Lymphoma
7.8. Others
8. GLOBAL ONCOLOGY BIOSIMILARS MARKET, BY DISTRIBUTION CHANNEL
8.1. Overview
8.2. Hospital Pharmacy
8.3. Retail Pharmacy
8.4. Online Pharmacy
9. GLOBAL ONCOLOGY BIOSIMILARS MARKET, BY REGION
9.1. Overview
9.1. North America
9.1.1. US
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. France
9.2.3. UK
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia-Pacific
9.3.1. China
9.3.2. India
9.3.3. Japan
9.3.4. South Korea
9.3.5. Australia
9.3.6. Rest of Asia-Pacific
9.4. Rest of the World
9.4.1. Middle East
9.4.2. Africa
9.4.3. Latin America
10. COMPETITIVE LANDSCAPE
10.1. Overview
10.2. Competitive Analysis
10.3. Market Share Analysis
10.4. Major Growth Strategy in the Global Oncology Biosimilars Market,
10.5. Competitive Benchmarking
10.6. Leading Players in Terms of Number of Developments in the Global Oncology Biosimilars Market,
10.7. Key developments and Growth Strategies
10.7.1. New Product Launch/Service Deployment
10.7.2. Merger & Acquisitions
10.7.3. Joint Ventures
10.8. Major Players Financial Matrix
10.8.1. Sales & Operating Income, 2023
10.8.2. Major Players R&D Expenditure. 2023
11. COMPANY PROFILES
11.1. Amgen Inc.
11.1.1. Company Overview
11.1.2. Financial Overview
11.1.3. Products Offered
11.1.4. Key Developments
11.1.5. SWOT Analysis
11.1.6. Key Strategies
11.2. Pfizer Inc.
11.2.1. Company Overview
11.2.2. Financial Overview
11.2.3. Products Offered
11.2.4. Key Developments
11.2.5. SWOT Analysis
11.2.6. Key Strategies
11.3. Celltrion Inc.
11.3.1. Company Overview
11.3.2. Financial Overview
11.3.3. Products Offered
11.3.4. Key Developments
11.3.5. SWOT Analysis
11.3.6. Key Strategies
11.4. Biocon Ltd.
11.4.1. Company Overview
11.4.2. Financial Overview
11.4.3. Products Offered
11.4.4. Key Developments
11.4.5. SWOT Analysis
11.4.6. Key Strategies
11.5. Samsung Bioepis Co., Ltd.
11.5.1. Company Overview
11.5.2. Financial Overview
11.5.3. Products Offered
11.5.4. Key Developments
11.5.5. SWOT Analysis
11.5.6. Key Strategies
11.6. Sandoz International GmbH
11.6.1. Company Overview
11.6.2. Financial Overview
11.6.3. Products Offered
11.6.4. Key Developments
11.6.5. SWOT Analysis
11.6.6. Key Strategies
11.7. Teva Pharmaceutical Industries Ltd.
11.7.1. Company Overview
11.7.2. Financial Overview
11.7.3. Products Offered
11.7.4. Key Developments
11.7.5. SWOT Analysis
11.7.6. Key Strategies
11.8. Mylan N.V.
11.8.1. Company Overview
11.8.2. Financial Overview
11.8.3. Products Offered
11.8.4. Key Developments
11.8.5. SWOT Analysis
11.8.6. Key Strategies
11.9. Merck & Co., Inc.
11.9.1. Company Overview
11.9.2. Financial Overview
11.9.3. Products Offered
11.9.4. Key Developments
11.9.5. SWOT Analysis
11.9.6. Key Strategies
11.10. STADA Arzneimittel AG
11.10.1. Company Overview
11.10.2. Financial Overview
11.10.3. Products Offered
11.10.4. Key Developments
11.10.5. SWOT Analysis
11.10.6. Key Strategies
12. APPENDIX
12.1. References
12.2. Related Reports
LIST OF TABLES
TABLE 1 GLOBAL ONCOLOGY BIOSIMILARS MARKET, SYNOPSIS, 2019-2032
TABLE 2 GLOBAL ONCOLOGY BIOSIMILARS MARKET, ESTIMATES & FORECAST, 2019-2032 (USD BILLION)
TABLE 3 GLOBAL ONCOLOGY BIOSIMILARS MARKET, BY DRUG, 2019-2032 (USD BILLION)
TABLE 4 GLOBAL ONCOLOGY BIOSIMILARS MARKET, BY DISEASE INDICATION, 2019-2032 (USD BILLION)
TABLE 5 GLOBAL ONCOLOGY BIOSIMILARS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 6 NORTH AMERICA: ONCOLOGY BIOSIMILARS MARKET, BY DRUG, 2019-2032 (USD BILLION)
TABLE 7 NORTH AMERICA: ONCOLOGY BIOSIMILARS MARKET, BY DISEASE INDICATION, 2019-2032 (USD BILLION)
TABLE 8 NORTH AMERICA: ONCOLOGY BIOSIMILARS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 9 US: ONCOLOGY BIOSIMILARS MARKET, BY DRUG, 2019-2032 (USD BILLION)
TABLE 10 US: ONCOLOGY BIOSIMILARS MARKET, BY DISEASE INDICATION, 2019-2032 (USD BILLION)
TABLE 11 US: ONCOLOGY BIOSIMILARS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 12 CANADA: ONCOLOGY BIOSIMILARS MARKET, BY DRUG, 2019-2032 (USD BILLION)
TABLE 13 CANADA: ONCOLOGY BIOSIMILARS MARKET, BY DISEASE INDICATION, 2019-2032 (USD BILLION)
TABLE 14 CANADA: ONCOLOGY BIOSIMILARS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 1 EUROPE: ONCOLOGY BIOSIMILARS MARKET, BY DRUG, 2019-2032 (USD BILLION)
TABLE 2 EUROPE: ONCOLOGY BIOSIMILARS MARKET, BY DISEASE INDICATION, 2019-2032 (USD BILLION)
TABLE 3 EUROPE: ONCOLOGY BIOSIMILARS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 4 GERMANY: ONCOLOGY BIOSIMILARS MARKET, BY DRUG, 2019-2032 (USD BILLION)
TABLE 5 GERMANY: ONCOLOGY BIOSIMILARS MARKET, BY DISEASE INDICATION, 2019-2032 (USD BILLION)
TABLE 6 GERMANY: ONCOLOGY BIOSIMILARS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 7 FRANCE: ONCOLOGY BIOSIMILARS MARKET, BY DRUG, 2019-2032 (USD BILLION)
TABLE 8 FRANCE: ONCOLOGY BIOSIMILARS MARKET, BY DISEASE INDICATION, 2019-2032 (USD BILLION)
TABLE 9 FRANCE: ONCOLOGY BIOSIMILARS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 10 ITALY: ONCOLOGY BIOSIMILARS MARKET, BY DRUG, 2019-2032 (USD BILLION)
TABLE 11 ITALY: ONCOLOGY BIOSIMILARS MARKET, BY DISEASE INDICATION, 2019-2032 (USD BILLION)
TABLE 12 ITALY: ONCOLOGY BIOSIMILARS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 13 SPAIN: ONCOLOGY BIOSIMILARS MARKET, BY DRUG, 2019-2032 (USD BILLION)
TABLE 14 SPAIN: ONCOLOGY BIOSIMILARS MARKET, BY DISEASE INDICATION, 2019-2032 (USD BILLION)
TABLE 15 SPAIN: ONCOLOGY BIOSIMILARS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 16 UK: ONCOLOGY BIOSIMILARS MARKET, BY DRUG, 2019-2032 (USD BILLION)
TABLE 17 UK: ONCOLOGY BIOSIMILARS MARKET, BY DISEASE INDICATION, 2019-2032 (USD BILLION)
TABLE 18 UK: ONCOLOGY BIOSIMILARS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 19 REST OF EUROPE: ONCOLOGY BIOSIMILARS MARKET, BY DRUG, 2019-2032 (USD BILLION)
TABLE 20 REST OF EUROPE: ONCOLOGY BIOSIMILARS MARKET, BY DISEASE INDICATION, 2019-2032 (USD BILLION)
TABLE 21 REST OF EUROPE: ONCOLOGY BIOSIMILARS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 22 ASIA-PACIFIC: ONCOLOGY BIOSIMILARS MARKET, BY DRUG, 2019-2032 (USD BILLION)
TABLE 23 ASIA-PACIFIC: ONCOLOGY BIOSIMILARS MARKET, BY DISEASE INDICATION, 2019-2032 (USD BILLION)
TABLE 24 ASIA-PACIFIC: ONCOLOGY BIOSIMILARS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 25 JAPAN: ONCOLOGY BIOSIMILARS MARKET, BY DRUG, 2019-2032 (USD BILLION)
TABLE 26 JAPAN: ONCOLOGY BIOSIMILARS MARKET, BY DISEASE INDICATION, 2019-2032 (USD BILLION)
TABLE 27 JAPAN: ONCOLOGY BIOSIMILARS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 28 CHINA: ONCOLOGY BIOSIMILARS MARKET, BY DRUG, 2019-2032 (USD BILLION)
TABLE 29 CHINA: ONCOLOGY BIOSIMILARS MARKET, BY DISEASE INDICATION, 2019-2032 (USD BILLION)
TABLE 30 CHINA: ONCOLOGY BIOSIMILARS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 31 INDIA: ONCOLOGY BIOSIMILARS MARKET, BY DRUG, 2019-2032 (USD BILLION)
TABLE 32 INDIA: ONCOLOGY BIOSIMILARS MARKET, BY DISEASE INDICATION, 2019-2032 (USD BILLION)
TABLE 33 INDIA: ONCOLOGY BIOSIMILARS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 34 AUSTRALIA: ONCOLOGY BIOSIMILARS MARKET, BY DRUG, 2019-2032 (USD BILLION)
TABLE 35 AUSTRALIA: ONCOLOGY BIOSIMILARS MARKET, BY DISEASE INDICATION, 2019-2032 (USD BILLION)
TABLE 36 AUSTRALIA: ONCOLOGY BIOSIMILARS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 37 SOUTH KOREA: ONCOLOGY BIOSIMILARS MARKET, BY DRUG, 2019-2032 (USD BILLION)
TABLE 38 SOUTH KOREA: ONCOLOGY BIOSIMILARS MARKET, BY DISEASE INDICATION, 2019-2032 (USD BILLION)
TABLE 39 SOUTH KOREA: ONCOLOGY BIOSIMILARS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 40 REST OF ASIA-PACIFIC: ONCOLOGY BIOSIMILARS MARKET, BY DRUG, 2019-2032 (USD BILLION)
TABLE 41 REST OF ASIA-PACIFIC: ONCOLOGY BIOSIMILARS MARKET, BY DISEASE INDICATION, 2019-2032 (USD BILLION)
TABLE 42 REST OF ASIA-PACIFIC: ONCOLOGY BIOSIMILARS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 43 REST OF THE WORLD: ONCOLOGY BIOSIMILARS MARKET, BY DRUG, 2019-2032 (USD BILLION)
TABLE 44 REST OF THE WORLD: ONCOLOGY BIOSIMILARS MARKET, BY DISEASE INDICATION, 2019-2032 (USD BILLION)
TABLE 45 REST OF THE WORLD: ONCOLOGY BIOSIMILARS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 46 MIDDLE EAST: ONCOLOGY BIOSIMILARS MARKET, BY DRUG, 2019-2032 (USD BILLION)
TABLE 47 MIDDLE EAST: ONCOLOGY BIOSIMILARS MARKET, BY DISEASE INDICATION, 2019-2032 (USD BILLION)
TABLE 48 MIDDLE EAST: ONCOLOGY BIOSIMILARS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 49 AFRICA: ONCOLOGY BIOSIMILARS MARKET, BY DRUG, 2019-2032 (USD BILLION)
TABLE 50 AFRICA: ONCOLOGY BIOSIMILARS MARKET, BY DISEASE INDICATION, 2019-2032 (USD BILLION)
TABLE 51 AFRICA: ONCOLOGY BIOSIMILARS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 52 LATIN AMERICA: ONCOLOGY BIOSIMILARS MARKET, BY DRUG, 2019-2032 (USD BILLION)
TABLE 53 LATIN AMERICA: ONCOLOGY BIOSIMILARS MARKET, BY DISEASE INDICATION, 2019-2032 (USD BILLION)
TABLE 54 LATIN AMERICA: ONCOLOGY BIOSIMILARS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL ONCOLOGY BIOSIMILARS MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL ONCOLOGY BIOSIMILARS MARKET
FIGURE 4 GLOBAL ONCOLOGY BIOSIMILARS MARKET, SHARE (%), BY DRUG, 2023
FIGURE 5 GLOBAL ONCOLOGY BIOSIMILARS MARKET, SHARE (%), BY DISEASE INDICATION, 2023
FIGURE 6 GLOBAL ONCOLOGY BIOSIMILARS MARKET, SHARE (%), BY DISTRIBUTION CHANNEL, 2023
FIGURE 7 GLOBAL ONCOLOGY BIOSIMILARS MARKET, SHARE (%), BY REGION, 2023
FIGURE 8 NORTH AMERICA: ONCOLOGY BIOSIMILARS MARKET, SHARE (%), BY REGION, 2023
FIGURE 9 EUROPE: ONCOLOGY BIOSIMILARS MARKET, SHARE (%), BY REGION, 2023
FIGURE 10 ASIA-PACIFIC: ONCOLOGY BIOSIMILARS MARKET, SHARE (%), BY REGION, 2023
FIGURE 11 REST OF THE WORLD: ONCOLOGY BIOSIMILARS MARKET, SHARE (%), BY REGION, 2023
FIGURE 12 GLOBAL ONCOLOGY BIOSIMILARS MARKET: COMPANY SHARE ANALYSIS, 2023 (%)
FIGURE 13 AMGEN INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 14 AMGEN INC.: SWOT ANALYSIS
FIGURE 15 PFIZER INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 16 PFIZER INC.: SWOT ANALYSIS
FIGURE 17 CELLTRION INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 18 CELLTRION INC.: SWOT ANALYSIS
FIGURE 19 BIOCON LTD.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 20 BIOCON LTD.: SWOT ANALYSIS
FIGURE 21 SAMSUNG BIOEPIS CO., LTD.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 22 SAMSUNG BIOEPIS CO., LTD.: SWOT ANALYSIS
FIGURE 23 SANDOZ INTERNATIONAL GMBH: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 24 SANDOZ INTERNATIONAL GMBH: SWOT ANALYSIS
FIGURE 25 TEVA PHARMACEUTICAL INDUSTRIES LTD.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 26 TEVA PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS
FIGURE 27 MYLAN N.V.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 28 MYLAN N.V.: SWOT ANALYSIS
FIGURE 29 MERCK & CO., INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 30 MERCK & CO., INC.: SWOT ANALYSIS
FIGURE 31 STADA ARZNEIMITTEL AG: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 32 STADA ARZNEIMITTEL AG: SWOT ANALYSIS
